Management of male erectile dysfunction: From the past to the future.
erectile dysfunction
hormonal replacement therapy
intracavernosal injection
low-intensity extracorporeal shock wave
penile prosthesis implantation
phosphodiesterase 5 inhibitor
stem cell injection therapy
vacuum erection device
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
01
2023
accepted:
13
02
2023
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Erectile dysfunction is a common disease of the male reproductive system, which seriously affects the life quality of patients and their partners. At present, erectile dysfunction is considered as a social-psychological-physiological disease with complex etiology and various treatment methods. Oral PDE5I is the first-line treatment for erectile dysfunction with the advantages of high safety, good effect and non-invasiveness. But intracavernosal injection, hormonal replacement therapy, vacuum erection device, penile prosthesis implantation can also be alternative treatments for patients have organic erectile dysfunction or tolerance to PDE5I. With the rapid development of technologies, some new methods, such as low-intensity extracorporeal shock wave and stem cell injection therapy can even repair the organic damage of the corpora cavernosa. These are important directions for the treatment of male erectile dysfunction in the future. In this mini-review, we will introduce these therapies in detail.
Identifiants
pubmed: 36923224
doi: 10.3389/fendo.2023.1148834
pmc: PMC10008940
doi:
Substances chimiques
Phosphodiesterase 5 Inhibitors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1148834Informations de copyright
Copyright © 2023 Wang, Wu, Xiang, Xiao and Hu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Urol Clin North Am. 2021 Nov;48(4):611-619
pubmed: 34602180
World J Mens Health. 2013 Aug;31(2):170-5
pubmed: 24044113
Stem Cell Res Ther. 2019 Dec 18;10(1):398
pubmed: 31852516
Andrology. 2023 Feb;11(2):257-269
pubmed: 35929992
Urology. 2021 Feb;148:173-178
pubmed: 33017615
Int J Impot Res. 2021 May;33(4):401-409
pubmed: 33204007
Genes Dev. 2005 May 15;19(10):1129-55
pubmed: 15905405
PLoS One. 2016 Jun 03;11(6):e0156725
pubmed: 27257818
Int J Impot Res. 2001 Jun;13(3):172-5
pubmed: 11525316
Nat Commun. 2020 Jun 1;11(1):2687
pubmed: 32483116
Sex Med Rev. 2015 Mar;3(1):11-23
pubmed: 27784568
Int J Impot Res. 2014 Sep-Oct;26(5):167-71
pubmed: 24830674
J Sex Med. 2012 Jan;9(1):259-64
pubmed: 22008059
Nat Rev Dis Primers. 2016 Feb 04;2:16003
pubmed: 27188339
Int J Urol. 2022 Apr;29(4):351-359
pubmed: 35080051
Eur Urol. 2010 Aug;58(2):243-8
pubmed: 20451317
J Sex Med. 2014 Oct;11(10):2439-48
pubmed: 25042722
Theranostics. 2019 Aug 14;9(22):6354-6368
pubmed: 31588222
J Sex Med. 2015 Jul;12(7):1638-45
pubmed: 26096365
JAMA. 2016 Nov 1;316(17):1838
pubmed: 27802547
Expert Opin Drug Saf. 2016;15(2):237-47
pubmed: 26646748
Clin Gerontol. 2021 May-Jun;44(3):307-315
pubmed: 33012263
Commun Biol. 2022 Jul 25;5(1):744
pubmed: 35879418
Eur Urol. 2000 Jan;37(1):50-5
pubmed: 10671785
Eur Urol. 2021 Sep;80(3):333-357
pubmed: 34183196
N Engl J Med. 1998 May 14;338(20):1397-404
pubmed: 9580646
Urol Int. 2018;101(3):358-365
pubmed: 30173210
BMC Endocr Disord. 2021 Jul 1;21(1):139
pubmed: 34210295
Sex Med Rev. 2019 Apr;7(2):321-328
pubmed: 29631980
Nat Rev Urol. 2022 Feb;19(2):84-100
pubmed: 34764451
Aging Male. 2012 Dec;15(4):258-62
pubmed: 23094956
J Sex Med. 2016 Feb;13(2):144-52
pubmed: 26953829
Eur Urol Focus. 2022 May;8(3):803-813
pubmed: 34034995
PLoS One. 2020 Nov 9;15(11):e0241509
pubmed: 33166302
Mol Cell Endocrinol. 2018 Apr 15;465:4-26
pubmed: 28865807
EBioMedicine. 2016 Jan 19;5:204-10
pubmed: 27077129
J Clin Endocrinol Metab. 2016 Aug;101(8):3096-104
pubmed: 27355400
Urol Clin North Am. 2021 Nov;48(4):513-525
pubmed: 34602172
Eur Urol. 2015 Oct;68(4):674-80
pubmed: 25817916
Stem Cell Res Ther. 2021 Jan 25;12(1):87
pubmed: 33494812
Sex Med Rev. 2021 Jan;9(1):123-132
pubmed: 32631812
Am J Mens Health. 2019 Mar-Apr;13(2):1557988319846749
pubmed: 31027441
Drugs Aging. 2018 Mar;35(3):175-187
pubmed: 29464656
J Sex Med. 2019 Feb;16(2):168-194
pubmed: 30770067
Andrologia. 2012 May;44 Suppl 1:370-5
pubmed: 21762189
Angiogenesis. 2011 Mar;14(1):47-59
pubmed: 21104120
Biomed Pharmacother. 2022 Apr;148:112765
pubmed: 35247715
Asian J Androl. 2017 Jan-Feb;19(1):91-97
pubmed: 27345005
Nat Rev Urol. 2016 May;13(5):266-74
pubmed: 26878803
JAMA Netw Open. 2020 Nov 2;3(11):e2021701
pubmed: 33185675
Rev Int Androl. 2021 Oct-Dec;19(4):272-280
pubmed: 32605764
Andrology. 2022 Nov;10(8):1567-1574
pubmed: 36088578
J Sex Med. 2018 Aug;15(8):1073-1082
pubmed: 29960891
J Urol. 2016 May;195(5):1550-1555
pubmed: 26694904
Sex Med Rev. 2019 Jan;7(1):115-128
pubmed: 30301707
J Sex Med. 2015 Apr;12(4):966-74
pubmed: 25648342
J Sex Med. 2016 Apr;13(4):465-88
pubmed: 27045254
N Engl J Med. 2016 Feb 18;374(7):611-24
pubmed: 26886521
BJU Int. 2004 Oct;94(6):904-9
pubmed: 15476533
Asian J Androl. 2013 May;15(3):387-90
pubmed: 23564044
BJU Int. 1999 Jul;84(1):50-6
pubmed: 10444124
Pharmaceutics. 2022 Sep 15;14(9):
pubmed: 36145702
Int J Impot Res. 2020 May;32(3):345-351
pubmed: 31477852
Arch Cardiovasc Dis. 2016 Jun-Jul;109(6-7):431-43
pubmed: 27184830
J Sex Med. 2013 Apr;10(4):1124-35
pubmed: 23347150
Zhonghua Nan Ke Xue. 2015 Mar;21(3):195-9
pubmed: 25898548
J Sex Med. 2017 Sep;14(9):1084-1094
pubmed: 28781215
Am J Med. 2007 Feb;120(2):151-7
pubmed: 17275456
J Sex Med. 2010 Apr;7(4 Pt 1):1391-400
pubmed: 20141586
World J Mens Health. 2021 Jan;39(1):48-64
pubmed: 32202086
Med Sci Monit. 2022 Mar 26;28:e935232
pubmed: 35338109